Discovering potential drug-targets for personalized treatment of autoimmune disorders - what we learn from epidermolysis bullosa acquisita.

Abstract

INTRODUCTION Epidermolysis bullosa acquisita (EBA) is a chronic autoimmune bullous dermatosis (AIBD). Treatment of EBA is challenging and mostly relies on systemic immunosuppression. During the last decade, intensive research led to the identification of new potential therapeutic targets that interfere in different phases of disease progression. Therapeutic… (More)

DOI: 10.1517/14728222.2016.1148686

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Cited By

Increased TREM-1 expression in inflamed skin has no functional impact on the pathogenesis of cutaneous disorders.

Sören Dräger, Kathrin Kalies, Talles B Sidronio, Mareike Witte, Ralf J Ludwig, Katja Bieber
Journal of dermatological science
2017

Regulatory T Cells Suppress Inflammation and Blistering in Pemphigoid Diseases

Katja Bieber, Shijie Sun, +13 authors Ralf J. Ludwig
Front. Immunol.
2017

Signalling and targeted therapy of inflammatory cells in epidermolysis bullosa acquisita.

Ralf J Ludwig
Experimental dermatology
2017

T cells mediate autoantibody-induced cutaneous inflammation and blistering in epidermolysis bullosa acquisita

Katja Bieber, Mareike Witte, +10 authors Ralf J. Ludwig
Scientific reports
2016

References

Sorry, we couldn't extract any references for this paper.

Slides referencing similar topics

Bone Marrow Transplantation for Epidermolysis Bullosa
Jakub Tolar + 2 • Oct 18, 2017
Ayurvedic Management of Autoimmune Disorders
Jayarajan Kodikannath + 9 • Jan 18, 2018
“ Screening ” for Autoimmune Disease
JENNIFER A. BRACKNEY • Oct 24, 2017
Show More